Cholinergic Basal Forebrain Integrity and Cognition in Parkinson’s Disease
Objective: To examine the association between the integrity of the cholinergic basal forebrain (cBF) and cognition in Parkinson’s disease (PD). Background: Most PD patients experience…Functional Connectivity Changes Associated with Interlimb Coordination Force Deficits in Parkinson’s Disease
Objective: To investigate differences in the functional connectivity of motor regions between individuals with and without Parkinson’s disease (PD) during a force task requiring coordination…Inflammation Biomarkers and Free Water Fraction in the Cholinergic Forebrain System in Idiopathic Parkinson’s Disease
Objective: Investigate if inflammatory biomarkers moderate the association between, cholinergic basal forebrain free water fraction and cholinergic innervation in idiopathic Parkinson’s disease. Background: The cholinergic…Improved Quantification of DAT-SPECT significantly increases its Performance as an Imaging Biomarker in Parkinson’s Disease
Objective: To investigate potential improvements in signal-to-noise (SNR) derived from advanced image analysis of longitudinal DAT-SPECT data. Background: [123I]Ioflupane SPECT (DAT-SPECT) has been widely used…Visual Hallucinations and Pareidolias Across the Lewy Body Disease Spectrum
Objective: To systemically evaluate visual hallucinations and illusions in patients across the LBD spectrum and to discover the underlying neural mechanism behind these visual symptoms.…Investigating the Use of 18F-DOPA PET/CT to Improve Diagnosis and Clinical Management of Parkinson’s Disease in South Australian Movement Disorder Clinics.
Objective: Evaluate the impact of 18F-DOPA PET/CT on clinical management for Parkinsonism. Background: Parkinson’s Disease affects >100,000 people in Australia with an economic burden of…Accuracy of AI-driven automated diagnostic software analyzing Susceptibility Map-Weighted Imaging to Differentiate Neurodegenerative from Non-neurodegenerative Parkinsonism
Objective: To determine the accuracy of AI-driven automated diagnostic software analyzing susceptibility map-weighted imaging (SMWI) to distinguish neurodegenerative from non-neurodegenerative parkinsonism in patients who had…LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization
Objective: To compare clinical and biomarker features and rate of progression among LRRK2-associated parkinsonism cases with and without in vivo evidence of pathologic alpha-synuclein (asyn)…Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…The Spatiotemporal Characteristics of Floor Sitting Rising in Parkinson’s Disease (PD)
Objective: To develop a method to characterize Floor Sitting Rising (FSR) in people with Parkinson disease (PwP). Background: Transitioning to the floor to a seated…
- « Previous Page
- 1
- …
- 434
- 435
- 436
- 437
- 438
- …
- 1942
- Next Page »